Pacer Advisors Inc. Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Share on StockTwits

Pacer Advisors Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.8% during the third quarter, Holdings Channel.com reports. The firm owned 33,947 shares of the medical equipment provider’s stock after acquiring an additional 4,113 shares during the period. Pacer Advisors Inc.’s holdings in Hologic were worth $1,714,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. CWM LLC raised its stake in Hologic by 3,466.7% during the second quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 520 shares in the last quarter. CSat Investment Advisory L.P. raised its stake in Hologic by 66.9% during the second quarter. CSat Investment Advisory L.P. now owns 831 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 333 shares in the last quarter. SevenBridge Financial Group LLC raised its stake in Hologic by 172.0% during the second quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock valued at $58,000 after purchasing an additional 762 shares in the last quarter. North Star Investment Management Corp. purchased a new stake in Hologic during the third quarter valued at $80,000. Finally, Private Capital Group LLC raised its stake in Hologic by 62.2% during the second quarter. Private Capital Group LLC now owns 2,327 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 892 shares in the last quarter. 95.29% of the stock is currently owned by institutional investors.

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus upped their price target on shares of Hologic from $43.00 to $48.00 and gave the company a “hold” rating in a research note on Monday, August 5th. BidaskClub downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday. Argus upped their price target on shares of Hologic to $62.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. BTIG Research reaffirmed a “buy” rating and set a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. Finally, Piper Jaffray Companies upped their price target on shares of Hologic from $49.00 to $59.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the stock. Hologic has an average rating of “Hold” and an average price target of $51.48.

In other news, Chairman Stephen P. Macmillan sold 194,396 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $48.77, for a total value of $9,480,692.92. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Peter J. Valenti III sold 7,766 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total transaction of $381,621.24. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

Shares of HOLX opened at $49.43 on Wednesday. Hologic, Inc. has a twelve month low of $37.47 and a twelve month high of $52.19. The company has a market cap of $13.04 billion, a P/E ratio of 20.59, a P/E/G ratio of 2.06 and a beta of 0.78. The company has a current ratio of 1.57, a quick ratio of 1.11 and a debt-to-equity ratio of 1.27. The company’s fifty day simple moving average is $49.29 and its 200-day simple moving average is $47.81.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.02. Hologic had a negative net margin of 0.89% and a positive return on equity of 27.95%. The business had revenue of $852.40 million for the quarter, compared to the consensus estimate of $836.91 million. During the same quarter in the prior year, the firm posted $0.58 earnings per share. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. Analysts predict that Hologic, Inc. will post 2.44 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Back-End Load

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Morgan Stanley Emerging Markets Domestic  Shares Pass Below 50-Day Moving Average of $6.83
Morgan Stanley Emerging Markets Domestic Shares Pass Below 50-Day Moving Average of $6.83
Alumasc Group  Reaches New 1-Year Low at $80.00
Alumasc Group Reaches New 1-Year Low at $80.00
Mainstreet Equity  Sets New 12-Month High at $68.00
Mainstreet Equity Sets New 12-Month High at $68.00
Berkwood Resources  Reaches New 52-Week Low at $0.02
Berkwood Resources Reaches New 52-Week Low at $0.02
Ooma  Issues Q4 Earnings Guidance
Ooma Issues Q4 Earnings Guidance
New Destiny Mining  Hits New 1-Year Low at $0.05
New Destiny Mining Hits New 1-Year Low at $0.05


© 2006-2019 Ticker Report